MD BSc - BioXcel Therapeutics VP Officer
| BTAI Stock | USD 0.57 0.02 3.39% |
Insider
MD BSc is VP Officer of BioXcel Therapeutics
| Age | 53 |
| Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
| Phone | 475 238 6837 |
| Web | https://www.bioxceltherapeutics.com |
BioXcel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6362) % which means that it has lost $0.6362 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.33, while Return On Tangible Assets are projected to decrease to (2.55). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.43, while Non Currrent Assets Other are projected to decrease to under 82.7 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ian Critchley | Spero Therapeutics | N/A | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Richard Hameister | Coherus BioSciences | N/A | |
| Prof MD | Hookipa Pharma | 80 | |
| Bryan Mcmichael | Coherus BioSciences | 45 | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| Angela MD | Spero Therapeutics | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Karen Kotz | Coherus BioSciences | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| MBA MD | Spero Therapeutics | 43 | |
| Rebecca Sunshine | Coherus BioSciences | 61 | |
Management Performance
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 |
BioXcel Therapeutics Leadership Team
Elected by the shareholders, the BioXcel Therapeutics' board of directors comprises two types of representatives: BioXcel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioXcel. The board's role is to monitor BioXcel Therapeutics' management team and ensure that shareholders' interests are well served. BioXcel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioXcel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Yocca, Chief Scientific Officer | ||
| Richard MBA, Senior CFO | ||
| Mary Coleman, VP Relations | ||
| Javier Rodriguez, Chief VP | ||
| Cedric Burg, VP Management | ||
| Robert Scala, Vice Planning | ||
| Chetan Lathia, Clinical Medicine | ||
| Robert MD, Chief Neuroscience | ||
| Krishnan Nandabalan, Chief Director | ||
| Vimal Mehta, President CEO, Secretary, Director | ||
| Matthew Wiley, Senior Officer | ||
| Iris Francesconi, Market Marketing | ||
| MD BSc, VP Officer | ||
| BSc MD, Chief VP | ||
| Friso Postma, Senior intelligence |
BioXcel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioXcel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (14.89) % | ||||
| Current Valuation | 89.72 M | ||||
| Shares Outstanding | 42.75 M | ||||
| Shares Owned By Insiders | 20.06 % | ||||
| Shares Owned By Institutions | 8.70 % | ||||
| Number Of Shares Shorted | 347.08 K | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.